Evaluation of cis-diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats☆
References (18)
- et al.
Methods for producing a reproducible crush in the sciatic and tibial nerve of the rat and rapid and precise testing of return of sensory function: Beneficial effects of melanocortins
J. Neurol. Sci.
(1986) - et al.
The importance of the Hoffman-reflex in the diagnosis of lumbar root lesions
Clin. Neurol. Neurosurg.
(1974) Sensory and motor nerve conduction velocities and the latency of the H-reflex during growth of the rat
Exp. Neurol.
(1981)- et al.
Neurotoxicity of cis-platinum: Pathology of the central and peripheral nervous systems
Neurology
(1980) - et al.
Antitumor activity, induction of cross-resistance and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum (II) sulfate, and of cis-diamminedichloroplantinum (II) in an immunocytoma model in the rat
Cancer Res.
(1983) - et al.
Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment
Cancer
(1979) Uber Beziehungen der Sehnenreflexe zur willkurlichen Beweging und zum Tonus
Z. Bio. (Munich)
(1918)- et al.
Observations on the nature of F-waves recorded in man
Neurology
(1967) - et al.
Effects of vincristine, maytansine and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat
J. Appl. Toxicol.
(1984)
Cited by (68)
The role of DNA damage and repair in toxicity to postmitotic cells caused by cancer therapies
2016, DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Second EditionCerebellum neurotransmission during postnatal development: [Pt(O,O'-acac)(γ-acac)(DMS)] vs cisplatin and neurotoxicity
2015, International Journal of Developmental NeuroscienceCitation Excerpt :The effects of cisplatin [cis-diamminedichloroplatinum(I)I] (cisPt), the most widely used drug in the chemotherapy of cancer (Brezden et al., 2000), in rodents is similar to that seen in patients. Several groups have studied the effects of cisPt on the peripheral nervous system of rats (De Koning et al., 1987; Holmes et al., 1998; Tomiwa et al., 1986) and mice (Carozzi et al., 2009). CisPt has been shown to be toxic to cell populations in culture (Bottone et al., 2008; Santin et al., 2011, 2013), to the developing CNS (Avella et al., 2006; Cerri et al., 2011; Piccolini et al., 2012; Pisu et al., 2004; review: Bernocchi et al., 2011).
Characterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy
2013, Pharmacology Biochemistry and BehaviorCitation Excerpt :On the contrary, the effects produced by cisplatin on thermal sensitivity remain controversial. Some studies have reported thermal hypoalgesia (Authier et al., 2003; Boyle et al., 1999) or hyperalgesia (Ta et al., 2009) whereas others have found no change (Hori et al., 2010; De Koning et al., 1987; Tredici et al., 1999; present results) in the responses to thermal stimulation following treatment with cisplatin. In humans, the heat pain threshold did not change in cisplatin-treated patients after 3, 6 or 9 cycles of chemotherapy (Attal et al., 2009).
The Role of DNA Damage and Repair in Neurotoxicity Caused by Cancer Therapies
2012, DNA Repair in Cancer TherapyThe Role of DNA Damage and Repair in Neurotoxicity Caused by Cancer Therapies
2011, DNA Repair in Cancer Therapy: Molecular Targets and Clinical ApplicationsUpregulations of P2X<inf>3</inf> and ASIC3 involve in hyperalgesia induced by cisplatin administration in rats
2010, PainCitation Excerpt :In our cumulative-dose protocol (15 mg/kg), cisplatin treatment had no effect on motor performance in the rota-rod test. This finding is consistent with previous reports that the motor nerve conduction velocity remained electrophysiologically unaffected, while the sensory nerve conduction velocity was reduced [15]. A previous study reported that administrations of cisplatin (total dose 32 mg/kg) intraperitoneally in female Dark Agouti rats produced reductions in both rota-rod performance and gait disturbance [9].
- ☆
Supported in part by a grant from the Koningin Wilhelmina Fonds.